Radio and PodcastLive Radio & PodcastsScience & Medicine
FDA requires warnings about increased risk of serious heart-related events, cancer, blood clots, and death for JAK inhibitors that treat certain chronic inflammatory conditions
Listen to an audio podcast of the September 1, 2021 FDA Drug Safety Communication on requiring revisions to the Boxed Warning for Xeljanz/Xeljanz XR, Olumiant, and Rinvoq to include information about the risks of serious...
About This Episode
FDA requires warnings about increased risk of serious heart-related events, cancer, blood clots, and death for JAK inhibitors that treat certain chronic inflammatory conditions is an episode from FDA Drug Safety Podcasts by U.S. Food and Dr...
Podcast
This episode belongs to FDA Drug Safety Podcasts.
Listen Online
Use the player on this page to stream the episode online.
Episode Details
Published Sep 8, 2021, 4:00 long, audio available.
Related Episodes
Continue listening to more episodes from FDA Drug Safety Podcasts.
Questions About This Episode
What is FDA requires warnings about increased risk of serious heart-related events, cancer, blood clots, and death for JAK inhibitors that treat certain chronic inflammatory conditions about?
Listen to an audio podcast of the September 1, 2021 FDA Drug Safety Communication on requiring revisions to the Boxed Warning for Xeljanz/Xeljanz XR, Olumiant, and Rinvoq to include information about the risks of serious heart-related events, cancer, blood clots, and death.
Where can I listen to FDA requires warnings about increased risk of serious heart-related events, cancer, blood clots, and death for JAK inhibitors that treat certain chronic inflammatory conditions?
You can listen to FDA requires warnings about increased risk of serious heart-related events, cancer, blood clots, and death for JAK inhibitors that treat certain chronic inflammatory conditions online on Radio and Podcast. Open the player on this page to stream the available audio.
Which podcast is FDA requires warnings about increased risk of serious heart-related events, cancer, blood clots, and death for JAK inhibitors that treat certain chronic inflammatory conditions from?
FDA requires warnings about increased risk of serious heart-related events, cancer, blood clots, and death for JAK inhibitors that treat certain chronic inflammatory conditions is an episode from FDA Drug Safety Podcasts by U.S. Food and Drug Administration, Center for Drug Evaluation and Research.
How long is this episode?
This episode is 4:00 long.
When was this episode published?
This episode was published on Sep 8, 2021.
Can I save FDA requires warnings about increased risk of serious heart-related events, cancer, blood clots, and death for JAK inhibitors that treat certain chronic inflammatory conditions for later?
Yes. Use the heart button on the episode page to add it to your favorite episodes list.
Are there related episodes from FDA Drug Safety Podcasts?
Yes. This page shows related episodes from FDA Drug Safety Podcasts when more episodes are available from the podcast feed.
Quick Answers About This Episode
Where can I listen to FDA requires warnings about increased risk of serious heart-related events, cancer, blood clots, and death for JAK inhibitors that treat certain chronic inflammatory conditions?
You can listen to FDA requires warnings about increased risk of serious heart-related events, cancer, blood clots, and death for JAK inhibitors that treat certain chronic inflammatory conditions on this page when the episode audio is available from the podcast feed.
Which podcast is this episode from?
FDA requires warnings about increased risk of serious heart-related events, cancer, blood clots, and death for JAK inhibitors that treat certain chronic inflammatory conditions is from FDA Drug Safety Podcasts by U.S. Food and Drug Administration, Center for Drug Evaluation and Research.
What are the episode details?
Published Sep 8, 2021 and 4:00 long